Neurosense Therapeutics LTD. (NRSNW) SEC Filings — 2024
45 SEC filings for Neurosense Therapeutics LTD. (NRSNW) in 2024.
Filings
- NeuroSense Therapeutics Advances PrimeC for ALS — 6-K · Dec 23, 2024
- NeuroSense Therapeutics Ltd. Reports Q3 2024 Results — 6-K · Dec 18, 2024
- NeuroSense Therapeutics Faces Nasdaq Delisting Warning — 6-K · Dec 17, 2024
- NeuroSense Gets FDA Nod on PrimeC Phase 3 Study Design — 6-K · Dec 11, 2024
- Neurosense Therapeutics LTD. SC 13G Filing — SC 13G · Dec 9, 2024
- NeuroSense Completes PARADIGM Study, PrimeC Shows ALS Benefits — 6-K · Dec 4, 2024
- NeuroSense Therapeutics Ltd. Private Placement Deal — 6-K · Dec 2, 2024
- NeuroSense Therapeutics Gets Nasdaq Continued Listing Approval — 6-K · Nov 12, 2024
- NeuroSense Therapeutics Secures Up to $15M Equity Line — 6-K · Oct 31, 2024
- NeuroSense Completes 18-Month ALS Trial Dosing — 6-K · Oct 30, 2024
- NeuroSense FDA Meeting Boosts ALS Trial and NDA Path — 6-K · Oct 28, 2024
- NeuroSense PrimeC Shows miRNA Improvement in ALS Patients — 6-K · Oct 24, 2024
- NeuroSense Advances ALS Treatment Commercialization in Canada — 6-K · Oct 15, 2024
- NeuroSense Plans Early ALS Treatment Commercialization in Canada — 6-K · Oct 9, 2024
- NeuroSense Therapeutics Files 6-K with Financials — 6-K · Sep 30, 2024
- NeuroSense Regains NASDAQ Compliance, Secures ALS Drug Patent — 6-K · Sep 24, 2024
- NeuroSense Therapeutics Starts HIPAA Compliance Process — 6-K · Sep 16, 2024
- NeuroSense Therapeutics Completes Key Toxicity Study Phase — 6-K · Sep 9, 2024
- NeuroSense Therapeutics Gets Nasdaq Minimum Bid Price Notice — 6-K · Aug 30, 2024
- NeuroSense in talks for PrimeC drug partnership — 6-K · Aug 28, 2024
- NeuroSense Therapeutics Faces Nasdaq Compliance Hearing — 6-K · Aug 26, 2024
- NeuroSense Therapeutics Signs Sales Agreement with JonesTrading — 6-K · Aug 16, 2024
- NeuroSense Therapeutics Private Placement with Management — 6-K · Aug 7, 2024
- NeuroSense Therapeutics Reports Positive ALS Trial Biomarker Data — 6-K · Aug 1, 2024
- NeuroSense ALS Trial Shows Significant Survival Benefit — 6-K · Jul 9, 2024
- NeuroSense Therapeutics Shareholders Approve All Resolutions — 6-K · Jul 3, 2024
- NeuroSense ALS Drug Shows Efficacy in PARADIGM Study — 6-K · Jul 1, 2024
- NeuroSense Therapeutics Amends Warrant Agreement — 6-K · Jun 27, 2024
- NeuroSense Therapeutics Reports Q1 2024 Results — 6-K · Jun 24, 2024
- NeuroSense Therapeutics to Appeal Nasdaq Delisting Notice — 6-K · Jun 21, 2024
- NeuroSense Therapeutics Files 6-K Report — 6-K · Jun 17, 2024
- NeuroSense Therapeutics Schedules Shareholder Meeting — 6-K · May 28, 2024
- NeuroSense Therapeutics Sets Annual Shareholder Meeting Date — 6-K · May 23, 2024
- NeuroSense VP to Speak at ALS Drug Summit — 6-K · May 20, 2024
- NeuroSense Partners with PhaseV for ALS Trial Optimization — 6-K · May 14, 2024
- NeuroSense ALS Trial Shows Disease Progression Slowdown — 6-K · May 7, 2024
- NeuroSense Therapeutics Announces Registered Direct Offering — 6-K · Apr 12, 2024
- NeuroSense Therapeutics Updates Investors with New Presentation — 6-K · Apr 10, 2024
- NeuroSense & Lonza Partner on Neurodegenerative Disease Biomarkers — 6-K · Apr 9, 2024
- NeuroSense Therapeutics Reports 2023 Financials & Business Update — 6-K · Apr 5, 2024
- NeuroSense Therapeutics Ltd. Files 20-F Annual Report for Fiscal Year Ended December 31, 2023 — 20-F · Apr 4, 2024
- NeuroSense Updates Presentation with Positive Clinical Outcomes — 6-K · Feb 22, 2024
- Neurosense Therapeutics LTD. SC 13G/A Filing — SC 13G/A · Feb 13, 2024
- NeuroSense Regains NASDAQ Minimum Bid Price Compliance — 6-K · Feb 7, 2024
- NeuroSense Updates Business Presentation with New Data on Slides 4 & 29 — 6-K · Jan 9, 2024